These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38247005)

  • 1. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P; Liu S; Cao H
    J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH; Lim T; Ham A; Kim YA; Lee M
    Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X; Yang M; Wang L; Li L; Zhong X
    Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
    Goff CB; Plaxe SC; White W; Dasanu CA
    J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S; Hirai H; Moriya C; Kusano Y; Hasegawa T
    Front Endocrinol (Lausanne); 2024; 15():1407192. PubMed ID: 38841300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
    Jouneghani NS; Phillip J; Dasanu CA
    J Oncol Pharm Pract; 2022 Apr; 28(3):722-724. PubMed ID: 34791931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
    Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
    JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
    Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
    Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
    Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
    Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune Checkpoint Inhibitors Related Diabetes Mellitus: 
A Report of 2 Cases and Literature Review].
    Ren Y; Zhang L; Wang Y; Zhong D
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):61-65. PubMed ID: 35078286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
    Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
    Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S; Kuriyama A; Tachibana H
    J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-induced type 1 diabetes.
    Maia A; Soares DM; Azevedo S; Pereira T; Amaral C
    J Oncol Pharm Pract; 2024 Sep; 30(6):1118-1121. PubMed ID: 38766907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
    Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
    J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.